Taysha Gene Therapies (TSHA) widens Q2 2026 loss but extends cash runway

Rhea-AI Filing Summary

Taysha Gene Therapies, Inc. reported second quarter 2026 results and clinical progress for TSHA-102 in Rett syndrome. Dosing was completed in the REVEAL pivotal trial (N=17) and ASPIRE trial (N=4), with TSHA-102 generally well tolerated across 33 patients with no severe treatment-related SAEs or DLTs. Longer-term REVEAL Part A data showed multi-domain functional gains deepening through at least 12 months post-treatment. The company expanded its commercial-readiness efforts, including a broader manufacturing partnership with Catalent.

Research and development expenses were $38.6 million, up from $20.1 million a year earlier, and general and administrative expenses were $12.1 million versus $8.6 million. Net loss for the quarter was $46.6 million, or $0.13 per share, compared with $26.9 million, or $0.09 per share. Following a $230.0 million follow-on offering, cash and cash equivalents totaled $455.4 million at June 30, 2026, which the company expects will fund operations into the second half of 2028. Topline data from the REVEAL pivotal six-month interim analysis and FDA feedback on the TSHA-102 BLA pathway are anticipated in the first half of 2027.

Positive

• $230.0 million follow-on offering strengthened liquidity, bringing cash to $455.4 million and extending the projected cash runway into the second half of 2028.
• Completed dosing in pivotal REVEAL (N=17) and ASPIRE (N=4) Rett syndrome trials, with TSHA-102 generally well tolerated across 33 patients and no severe treatment-related SAEs or DLTs.

Negative

• Quarterly net loss increased to $46.6 million from $26.9 million, driven by higher R&D and commercial-preparedness spending.
• Revenue declined to $0 in Q2 2026 from $1.986 million in Q2 2025, increasing reliance on external financing and existing cash.

Filing Explained

The completed financing is accompanied by 325,302,280 shares outstanding, reducing unchanged holders’ percentage ownership; the update is furnished, not filed.

This Form 8-K furnishes, rather than files, the company’s second-quarter results and corporate update under Item 2.02; it reports a completed $230.0 million follow-on financing and 325,302,280 common shares issued and outstanding as of June 30, 2026.

Because issuing additional shares increases the total share count and reduces an existing holder’s percentage ownership absent offsetting changes, a holder whose share count did not change has a smaller percentage ownership after the financing-related increase in the reported share base: 325,302,280 shares at June 30, 2026, versus 285,051,648 at December 31, 2025.

The balance sheet separately reports 700,000,000 authorized common shares; that authorization is not reported as issued and outstanding shares.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Key Figures

Research and development expenses Q2 2026: $38.6 million General and administrative expenses Q2 2026: $12.146 million Net loss Q2 2026: $46.639 million +5 more

8 metrics

Research and development expenses Q2 2026 $38.6 million For the three months ended June 30, 2026; up from $20.1 million in Q2 2025

General and administrative expenses Q2 2026 $12.146 million For the three months ended June 30, 2026; compared with $8.598 million in Q2 2025

Net loss Q2 2026 $46.639 million For the three months ended June 30, 2026; versus $26.882 million in Q2 2025

Cash and cash equivalents $455.407 million Balance as of June 30, 2026, after a $230.0 million follow-on financing

Follow-on offering gross proceeds $230.0 million June 2026 follow-on financing, including full exercise of underwriters’ option

Weighted average shares Q2 2026 369,044,040 shares Weighted average common shares outstanding, basic and diluted, for Q2 2026

Patients treated with TSHA-102 33 patients Across REVEAL Phase 1/2, pivotal and ASPIRE Rett syndrome trials at August 2026 cutoff

Total assets June 30, 2026 $470.433 million Total assets on the condensed consolidated balance sheet as of June 30, 2026

Key Terms

REVEAL pivotal trial, BLA submission pathway, miRNA-Responsive Auto-Regulatory Element (miRARE), Breakthrough Therapy, +2 more

6 terms

REVEAL pivotal trial medical

"Completed dosing in the REVEAL pivotal (N=17) and ASPIRE (N=4) trials"

BLA submission pathway regulatory

"expect to report topline data from 6-month interim analysis and FDA feedback on the BLA submission pathway"

miRNA-Responsive Auto-Regulatory Element (miRARE) technical

"TSHA-102 utilizes a novel miRNA-Responsive Auto-Regulatory Element (miRARE) technology"

Breakthrough Therapy regulatory

"TSHA-102 has received Breakthrough Therapy, Regenerative Medicine Advanced Therapy, Fast Track"

A breakthrough therapy is a regulatory designation granted to an experimental drug or treatment when early clinical evidence indicates it could offer a substantial improvement over existing options for a serious or life‑threatening condition. For investors it matters because the label brings faster, more intensive interaction with regulators and can shorten development and review time—like a VIP fast‑track toward potential approval, reducing time and risk before a product can reach the market.

Regenerative Medicine Advanced Therapy regulatory

"received Breakthrough Therapy, Regenerative Medicine Advanced Therapy, Fast Track and Orphan Drug"

Regenerative Medicine Advanced Therapy (RMAT) is a U.S. regulatory designation for cell, gene, and tissue‑based therapies intended to treat serious or life‑threatening conditions; it gives developers a “fast lane” with more frequent agency interaction and eligibility for accelerated review pathways. For investors, an RMAT label signals that a therapy may reach market faster and face less regulatory uncertainty than a standard program, which can raise the potential value and reduce timeline risk—though it is not a guarantee of approval.

Rett syndrome medical

"TSHA-102 is a self-complementary intrathecally delivered AAV9 investigational gene transfer therapy in clinical evaluation for Rett syndrome"

A rare genetic disorder that disrupts normal brain development in young children, most commonly girls, leading to slowed growth, loss of purposeful hand use, repetitive hand movements, motor problems, speech loss, and cognitive and breathing irregularities. Investors watch it because its severity and few treatment options create clear medical need and potential markets for therapies; think of it as a broken traffic signal in the brain that, if fixed, could restore many downstream functions.

Earnings Snapshot

Revenue Q2 2026: $0

Three and six months ended June 30, 2026

Revenue Q2 2026 $0 Decreased from $1.986 million in Q2 2025

Net loss Q2 2026 $46.639 million Increased from $26.882 million in Q2 2025

Research and development expenses Q2 2026 $38.636 million Increased from $20.141 million in Q2 2025

General and administrative expenses Q2 2026 $12.146 million Increased from $8.598 million in Q2 2025

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding 8-K Material Events →

Available on EDGAR 08/11/2026 - 04:07 PM Accepted by SEC EDGAR 08/11/2026 - 04:05 PM Learn about SEC filing dates

FAQ

What were Taysha Gene Therapies (TSHA) key financial results for Q2 2026?

Taysha reported a Q2 2026 net loss of $46.6 million, or $0.13 per share, versus a $26.9 million loss, or $0.09 per share, in Q2 2025. R&D expenses were $38.6 million and general and administrative expenses were $12.1 million.

How much cash does Taysha Gene Therapies (TSHA) have and what is its runway?

As of June 30, 2026, Taysha held $455.4 million in cash and cash equivalents, reflecting a $230.0 million follow-on offering. The company expects these resources to fund operations into the second half of 2028.

What progress did Taysha Gene Therapies (TSHA) report on TSHA-102 trials?

Taysha completed dosing in the REVEAL pivotal (N=17) and ASPIRE (N=4) Rett syndrome trials. Across 33 treated patients, TSHA-102 has been generally well tolerated with no severe treatment-related SAEs or DLTs, and longer-term data show multi-domain functional gains.

When will Taysha Gene Therapies (TSHA) report pivotal TSHA-102 data and FDA feedback?

Taysha anticipates topline data from the REVEAL pivotal trial six-month interim analysis and FDA feedback on the BLA submission pathway for TSHA-102 in the first half of 2027.

What caused higher operating expenses for Taysha Gene Therapies (TSHA) in Q2 2026?

Operating expenses rose to $47.3 million, primarily due to BLA-enabling PPQ manufacturing work and higher clinical costs for REVEAL and ASPIRE, plus increased compensation and commercial launch-readiness consulting and professional fees.

What designations has TSHA-102 received from regulators according to Taysha (TSHA)?

TSHA-102 has FDA Breakthrough Therapy, Regenerative Medicine Advanced Therapy, Fast Track, Orphan Drug and Rare Pediatric Disease designations, plus Orphan Drug from the European Commission and Innovative Licensing and Access Pathway designation from the U.K. regulator.

false 0001806310 0001806310 2026-08-11 2026-08-11

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 11, 2026

Taysha Gene Therapies, Inc.

(Exact name of registrant as specified in its Charter)

Delaware		001-39536		84-3199512
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

3000 Pegasus Park Drive, Suite 1430
Dallas, Texas		75247
(Address of Principal Executive Offices)		(Zip Code)

(214) 612-0000

(Registrant’s Telephone Number, Including Area Code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.00001 par value		TSHA		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On August 11, 2026, Taysha Gene Therapies, Inc. reported financial results for the quarter ended June 30, 2026, and recent business highlights. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference.

The information in this Item 2.02 of this Current Report on Form 8-K (including Exhibit 99.1) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Press Release, dated August 11, 2026.
104		Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

				Taysha Gene Therapies, Inc.
Dated: August 11, 2026				By:		/s/ Kamran Alam
						Kamran Alam
						Chief Financial Officer

Exhibit 99.1

Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Completed dosing in the REVEAL pivotal (N=17) and ASPIRE (N=4) trials evaluating TSHA-102 for Rett syndrome; expect to report topline data from 6-month interim analysis and FDA feedback on the BLA submission pathway in 1H 2027

TSHA-102 continues to be generally well tolerated with no severe treatment-related SAEs or DLTs across REVEAL Phase 1/2, pivotal and ASPIRE trials (N=33) as of the August 2026 data cutoff

Longer-term REVEAL Part A data demonstrated broad, multi-domain functional gains that deepened through ≥12 months post-TSHA-102, with consistent responses across ages and disease severity

Advanced TSHA-102 commercial readiness activities, including market access planning initiatives and expansion of strategic partnership with Catalent to support future commercial manufacturing

Completed $230 million follow-on offering, extending cash runway into 2H 2028 and through potential BLA approval of TSHA-102

Conference call and webcast today at 4:30 PM ET

Dallas – August 11, 2026 – Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today reported financial results for the second quarter ended June 30, 2026, and provided a corporate update.

“During the second quarter, we continued to execute against our clinical development strategy for TSHA-102 while advancing key commercial and manufacturing readiness initiatives in support of a potential BLA submission,” said Sean P. Nolan, Chairman and Chief Executive Officer of Taysha. “The completion of dosing in our REVEAL pivotal and ASPIRE trials, as well as positive longer-term follow-up data from our REVEAL Phase 1/2 trials continues to strengthen our conviction in TSHA-102 as a potentially transformative therapy for this devastating disease with high unmet need. In addition, the favorable safety profile observed to date across a broad and diverse patient population supports TSHA-102’s potential to safely deliver durable, meaningful functional benefits.”

Mr. Nolan continued, “We are working diligently to advance our commercial readiness activities to support the potential launch of TSHA-102, if approved. Our ongoing market and payer research continues to inform our market access strategy and reinforces TSHA-102’s significant value proposition and reimbursement potential. We have also expanded our partnership with Catalent, establishing a robust commercial supply framework to support the potential launch of TSHA-102 and strong demand we expect following potential FDA approval. Looking ahead, with a strengthened balance sheet, we remain focused on executing our BLA-enabling activities and anticipate reporting topline data from the REVEAL pivotal trial six-month interim analysis and FDA feedback on the BLA submission pathway in the first half of 2027.”

Recent Corporate and TSHA-102 Program Highlights

• Completed Dosing in the REVEAL Pivotal Trial. Taysha completed dosing in the overenrolled REVEAL pivotal trial, with a total of 17 patients in the developmental plateau population of Rett syndrome dosed with TSHA-102. The REVEAL pivotal trial is a single-arm, open-label trial evaluating a single intrathecal (IT) administration of high dose TSHA-102 (1x10¹⁵ total vector genomes (vg)) in females with Rett syndrome between the ages of 6 to <22 years. The primary endpoint will assess response rate, defined as the percentage of patients who gain or regain ≥one of the 28 natural history-defined developmental milestones, with each patient serving as their own control.

• The study includes a 6-month interim analysis that may serve as the basis for Biologics License Application (BLA) submission. The interim analysis is expected to occur after all 17 patients complete six months of post-treatment follow-up. Subsequently, Taysha plans to discuss data from the 6-month interim analysis and next steps in the BLA submission pathway with the U.S. Food and Drug Administration (FDA) and is on track to report topline data and regulatory feedback in 1H 2027.

• Completed Dosing in the ASPIRE Trial. Taysha completed dosing in the overenrolled ASPIRE trial, with a total of four patients with Rett syndrome, aged 2 to <4 years, dosed with TSHA-102. The safety-focused trial is evaluating the safety and preliminary efficacy of a single IT administration of high dose TSHA-102 (1x10¹⁵ total vg), scaled to account for the lower brain volume in 2 to <4-year-olds. ASPIRE is designed to support a planned BLA submission to enable broad labeling of TSHA-102 for patients aged ≥2 years with Rett syndrome. A minimum of three months of ASPIRE safety data will be included in the planned BLA submission, while efficacy in the 2 to <6-year-old population will be extrapolated from data collected in the REVEAL pivotal trial.

• TSHA-102 Continues to be Generally Well-Tolerated. High dose (1x10¹⁵ total vg) and low dose (5.7x10¹⁴ total vg) TSHA-102 continue to be generally well tolerated with no severe treatment-related serious adverse events (SAEs) or dose limiting toxicities (DLTs) in all patients treated in the REVEAL Phase 1/2, REVEAL pivotal and ASPIRE trials (N=33) as of the August 2026 data cutoff.

• Presented Data Supporting TSHA-102 Clinical Program at IRSF. Four poster presentations were delivered at the 2026 International Rett Syndrome Foundation (IRSF) Rett Syndrome Scientific Meeting. The posters, which are available on the Company’s website, highlighted:

• Longer-term REVEAL Part A data (May 2026 data cutoff), demonstrating broad, multi-domain functional gains that deepened over time through ≥12 months post-TSHA-102 regardless of patient age, disease severity or genotype

• Rett syndrome natural history data analysis showing a clear developmental plateau after 6 years of age, supporting a stable, well-defined population to evaluate TSHA-102 in the REVEAL pivotal trial

• Methods evaluation study data supporting the developmental milestone assessment (DMA) as a psychometrically valid, FDA-supported primary endpoint for single-arm interventional studies

• Preclinical data demonstrating superior MeCP2 expression of self-complementary AAV9 compared to single-stranded AAV9

• Advanced Commercial Readiness Activities to Support Potential Launch of TSHA-102.

• Completed payer research to inform market access planning, which demonstrated strong support for TSHA-102’s significant value proposition and reimbursement potential, including:

• TSHA-102 was viewed as a high-value therapy due to its transformative disease-modifying potential in a population with high unmet need, combined with the convenience of a one-time IT administration that can be performed in an outpatient setting

• Payers emphasized the importance of demonstrating clinically meaningful, durable functional gains and improvements that translate into real-world benefits

• Strong efficacy, safety and durability are expected to drive coverage and reimbursement, with durable functional benefits serving as the key value determinant in this high unmet need setting

• Expanded strategic partnership with Catalent, whereby Catalent will provide Good Manufacturing Practices (GMP) manufacturing and commercial supply of TSHA-102 at its FDA-licensed commercial gene therapy facility in Harmans, Maryland and will serve as Taysha’s primary commercial manufacturing partner following potential FDA approval. The agreement establishes a long-term commercial supply framework intended to support commercial launch and future demand. Catalent will leverage its experience across more than 90 gene therapy programs, including multiple commercial products.

• Strengthened Legal and Compliance Leadership through the Appointment of Mike Johannesen as Chief Legal Officer in June 2026. Mr. Johannesen brings over three decades of experience in corporate law, governance, compliance and strategic transactions across the biopharmaceutical and healthcare industries, having held executive roles at Advanced Medicine Partners, Jaguar Gene Therapy and AveXis.

• Completed Public Follow-on Offering with Total Gross Proceeds of $230 Million. Proceeds included full exercise of the underwriters’ option to purchase additional shares; anticipated cash runway extends into the second half of 2028 and through potential BLA approval of TSHA-102.

Anticipated Milestones

• Completion of BLA-enabling Process Performance Qualification (PPQ) campaign for TSHA-102 is expected in the fourth quarter of 2026

• Topline data from REVEAL pivotal trial 6-month interim analysis and FDA feedback on the BLA submission pathway for TSHA-102 is expected in the first half of 2027

Second Quarter 2026 Financial Highlights

Research and Development Expenses: Research and development expenses were $38.6 million for the three months ended June 30, 2026, compared to $20.1 million for the three months ended June 30, 2025. The $18.5 million increase was primarily driven by BLA-enabling PPQ manufacturing initiatives performed during the three months ended June 30, 2026, and higher clinical expenses from the REVEAL and ASPIRE trials. Compensation expenses, including non-cash stock-based compensation, also increased as a result of additional research and development headcount.

General and Administrative Expenses: General and administrative expenses were $12.1 million for the three months ended June 30, 2026, compared to $8.6 million for the three months ended June 30, 2025. The increase of $3.5 million was primarily due to higher compensation expenses, including non-cash stock-based compensation expense, and increases in consulting and professional fees, including commercial launch-readiness initiatives.

Net Loss: Net loss for the three months ended June 30, 2026, was $46.6 million, or $0.13 per share, compared to a net loss of $26.9 million, or $0.09 per share, for the three months ended June 30, 2025. 

Cash and Cash Equivalents: As of June 30, 2026, Taysha had $455.4 million in cash and cash equivalents. This reflects the gross proceeds of $230.0 million from the June 2026 follow-on financing, including full exercise of the underwriters’ option to purchase additional shares. The Company expects that its current cash resources will support planned operating expenses and capital requirements into the second half of 2028.

Conference Call and Webcast Information

Taysha management will host a live conference call and webcast today at 4:30 p.m. ET to review its financial and operating results and provide a corporate update. Participants may access the live webcast of the conference call by visiting Taysha’s website.

About TSHA-102

TSHA-102 is a self-complementary intrathecally delivered AAV9 investigational gene transfer therapy in clinical evaluation for Rett syndrome. Designed as a one-time treatment, TSHA-102 aims to address the genetic root cause of the disease by delivering a functional form of MECP2 to cells in the CNS. TSHA-102 utilizes a novel miRNA-Responsive Auto-Regulatory Element (miRARE) technology designed to mediate levels of MECP2 in the CNS on a cell-by-cell basis without risk of overexpression. TSHA-102 has received Breakthrough Therapy, Regenerative Medicine Advanced Therapy, Fast Track and Orphan Drug and Rare Pediatric Disease designations from the FDA, Orphan Drug designation from the European Commission and Innovative Licensing and Access Pathway designation from the Medicines and Healthcare products Regulatory Agency.

About Rett Syndrome

Rett syndrome is a rare neurodevelopmental disorder caused by mutations in the X-linked MECP2 gene encoding methyl CpG-binding protein 2 (MeCP2), which is essential for regulating neuronal and synaptic function in the brain. The disorder is characterized by loss of communication and hand function, slowing and/or regression of development, motor and respiratory impairment, seizures, intellectual disabilities and shortened life expectancy. Rett syndrome progression is divided into four key stages, beginning with early onset stagnation at 6 to 18 months of age followed by rapid regression, plateau and late motor deterioration. Rett syndrome primarily occurs in females and is one of the most common genetic causes of severe intellectual disability. Currently, there are no approved disease-modifying therapies that treat the genetic root cause of the disease. Rett syndrome caused by a pathogenic/likely pathogenic MECP2 mutation is estimated to affect between 15,000 and 20,000 patients in the U.S., EU, and U.K.

About Taysha Gene Therapies

Taysha Gene Therapies (Nasdaq: TSHA) is a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. Its lead clinical program TSHA-102 is in development for Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. With a singular focus on developing transformative medicines, Taysha aims to address severe unmet medical needs and dramatically improve the lives of patients and their caregivers. The Company’s management team has proven experience in gene therapy development and commercialization. Taysha leverages this experience, its manufacturing process and a clinically and commercially proven AAV9 capsid in an effort to rapidly translate treatments from bench to bedside. For more information, please visit www.tayshagtx.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipates,” “believes,” “expects,” “intends,” “projects,” “plans,” and “future” or similar expressions are intended to identify forward-looking statements. Forward-looking statements include, but are not limited to, statements concerning the potential of TSHA-102 and Taysha’s other product candidates to positively impact quality of life and alter the course of disease in the patients Taysha seeks to treat, Taysha’s research, development, regulatory and manufacturing plans for its product candidates, communications with the FDA, including with respect to the BLA for TSHA-102, the potential for Taysha’s product candidates to receive regulatory approval from the FDA or equivalent foreign regulatory agencies, and whether, if approved, these product candidates will be successfully distributed and marketed and the potential market opportunity for Taysha’s product candidates, Taysha’s commercial readiness activities, and the ability of Taysha’s current cash resources to support planned operating expenses into second half of 2028. Forward-looking statements are based on management’s current expectations and are subject to various risks and uncertainties that could cause actual results to differ materially and adversely from those expressed or implied by such forward-looking statements. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding Taysha’s business are described in detail in Taysha’s Securities and Exchange Commission (“SEC”) filings, including in our Annual Report on Form 10-K for the full-year ended December 31, 2025, which are available on the SEC’s website at www.sec.gov. Additional information will be made available in other filings that Taysha makes from time to time with the SEC. These forward-looking statements speak only as of the date hereof, and Taysha disclaims any obligation to update these statements except as may be required by law.

Taysha Gene Therapies, Inc.

Condensed Consolidated Statements of Operations

(in thousands, except share and per share data)

		For the Three Months Ended June 30,								For the Six Months Ended June 30,
		2026				2025				2026				2025
Revenue		$	—			$	1,986			$	—			$	4,288
Operating expenses:
Research and development			38,636				20,141				72,445				35,706
General and administrative			12,146				8,598				21,823				16,756
Net gain on lease termination			(3,433	)			—				(3,433	)			—
Total operating expenses			47,349				28,739				90,835				52,462
Loss from operations			(47,349	)			(26,753	)			(90,835	)			(48,174	)
Other income (expense):
Change in fair value of warrant liability			—				(273	)			—				(171	)
Change in fair value of term loan			(1,521	)			(1,461	)			(2,991	)			(2,991	)
Interest income			2,325				1,859				4,911				3,185
Interest expense			(6	)			(17	)			(15	)			(36	)
Other expense			(88	)			(237	)			(119	)			(224	)
Total other income (expense), net			710				(129	)			1,786				(237	)
Net loss		$	(46,639	)		$	(26,882	)		$	(89,049	)		$	(48,411	)
Net loss per common share, basic and diluted		$	(0.13	)		$	(0.09	)		$	(0.24	)		$	(0.17	)
Weighted average common shares outstanding, basic and diluted			369,044,040				297,988,978				367,845,094				283,726,888

Taysha Gene Therapies, Inc.

Condensed Consolidated Balance Sheet Data

(in thousands, except share and per share data)

		June 30, 2026				December 31, 2025
ASSETS
Current assets:
Cash and cash equivalents		$	455,407			$	319,767
Restricted cash			—				449
Prepaid expenses and other current assets			6,027				4,431
Total current assets			461,434				324,647
Restricted cash			164				2,315
Property, plant and equipment, net			2,412				6,736
Operating lease right-of-use assets			6,317				9,439
Other non-current assets			106				183
Total assets		$	470,433			$	343,320
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable		$	9,164			$	6,275
Accrued expenses and other current liabilities			16,811				20,277
Total current liabilities			25,975				26,552
Term loan, net			49,260				50,106
Operating lease liability, net of current portion			6,291				18,172
Other non-current liabilities			1,641				1,552
Total liabilities			83,167				96,382
Stockholders’ equity
Preferred stock, $0.00001 par value per share; 10,000,000 shares authorized and no shares issued and outstanding as of June 30, 2026, and December 31, 2025, respectively			—				—
Common stock, $0.00001 par value per share; 700,000,000 shares authorized and 325,302,280 and 285,051,648 issued and outstanding as of June 30, 2026 and December 31, 2025, respectively			3				3
Additional paid-in capital			1,186,843				958,427
Accumulated other comprehensive income (loss)			769				(192	)
Accumulated deficit			(800,349	)			(711,300	)
Total stockholders’ equity			387,266				246,938
Total liabilities and stockholders’ equity		$	470,433			$	343,320

Company Contact:

Hayleigh Collins

Vice President, Corporate Communications and Investor Relations

Taysha Gene Therapies, Inc.

hcollins@tayshagtx.com

Media Contact:

Media@tayshagtx.com

Filing Exhibits & Attachments

4 documents

Press Releases

• EX-99.1 EX-99.1 86.0 KB

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA 3.1 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE 17.6 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE 11.0 KB